Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)

AIDS

Volumn 13, Issue 7, 1999, Pages

  Cohen Stuart, James W T ^c   Schuurman, Rob ^c   Burger, David M ^c   Koopmans, Peter P ^c   Sprenger, Herman G ^c   Juttmann, Job R ^c   Richter, C ^c   Meenhorst, Pieter L ^c   Hoetelmans, Richard M W ^c   Kroon, Frank P ^c   Bravenboer, Bert ^c   Hamann, Dörte ^a   Boucher, Charles A B ^c   Borleffs, Jan C C ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NONE

Author keywords

Clinical trials; Combination therapy; Indinavir; Saquinavir soft gelatin capsule formulation

Indexed keywords

CD4 ANTIGEN; GELATIN; INDINAVIR; LAMIVUDINE; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BLADDER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; GASTRITIS; HEMATEMESIS; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CAPSULES; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; GELATIN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SAQUINAVIR; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 2142810054     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905070-00001     Document Type: Article

References (16)

1. 1. Stellbrink HJ, for the Invirase International Phse II Trial (SV-14604) Group: Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection. Hamburg, October 1997 [abstract 212].
2. 2. Buss N, on behalf of the Fortovase(r) Study Group, Roche Products Ltd, Welwyn Garden City, UK: Saquinavir soft gel capsule (Fortovase(r)): pharmacokinetics and drug interactions. Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 354].
3. 3. Mitsuyasu RT, Skolnik PR, Cohen SR, et al.: Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS 1998, 12:F103-F109.
4. 4. Lalezari J on behalf of the NV15107 study group: Selecting the optimum dose for a new soft gelatin cpsule formulation of saquinavir. J Acquir Immune Def Syndr Hum Retrovirol 1998, 19:195-196.
5. 5. Thompson M, on behalf of the NV15355 study team: Activity of soft gelatin capsule formulation of saquinavir in combination with two nucleosides in treatment-naive HIV-1-seropositive persons. World AIDS Conference. Geneva, June-July 1998 [abstract 12145].
6. 6. Farthing CM, Pilson SR, Siemon-Hryczyk P: Saquinavir (SQV) soft gel capsule (SGC) in combination with AZT and 3TC in antiretroviral-naive HIV-1 infected patients. World AIDS Conference. Geneva, June-July 1998 [abstract 12301].
7. 7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
8. 8. Drusano GL, Stein DS: Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob Agents Chemother 1998, 42:358-361.
9. 9. Pakker NG, Notermans DW, de Boer RJ, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998, 4:208-214.
10. 10. Levy JA, Ramachandran B, Barker E, Guthrie J, Elbeik T: Plasma viral load, CD4+ cell counts, and HIV-1 production by cells. Science 1996, 271:670-671.
11. 11. Milazzo L, Vaira LM, Cremoni L: CD4+ lymphocyte count variations in HIV-negative subjects treated with zidovudine [letter]. AIDS 1996, 10:1444-1445.
12. 12. Barker E, Kahn J, Fujimura S, Levy JA: Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals. AIDS 1998, 12:1117-1118.
13. 13. Casado JL, Perez-Elias MJ, Antela A, et al.: Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998, 12: F131-F135.
14. 14. Saag MS, Cloud GC, Raper J et al.: Predictors of success of antiretroviral therapy (ART) in a prospective clinic cohort, World AIDS Conference. Geneva, June-July 1998 [abstract 22363].
15. 15. Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J: Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS 1998, 12:1483-1490.
16. 16. Weverling GJ, Lange JMA, Jurriaans S, et al.: Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117-F222.